Home > Boards > US Listed > Biotechs > Assembly Biosciences, Inc. (ASMB)

ASMB—(-37%/AH)—suffers_massive_phase-2_failure in HBV:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 751
Posts 115,508
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/7/2021 4:16:27 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/7/2021 4:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2021 4:48:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2021 4:42:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2021 4:40:05 PM
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 3/5/2021 5:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2021 4:01:10 PM
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of... GlobeNewswire Inc. - 2/26/2021 7:30:00 AM
Assembly Biosciences EPS misses by $0.19, misses on revenue Seeking Alpha - 2/25/2021 4:33:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 4:13:42 PM
Assembly Biosciences scraps Phase 3 vebicorvir study plans Seeking Alpha - 2/25/2021 4:05:56 PM
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights GlobeNewswire Inc. - 2/25/2021 4:05:00 PM
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infec... GlobeNewswire Inc. - 2/25/2021 4:00:00 PM
Assembly Bio Announces Upcoming Investor Events GlobeNewswire Inc. - 2/19/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/17/2021 4:56:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/17/2021 3:08:23 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 5:24:25 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 4:26:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 7:04:27 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 6:50:55 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/10/2021 10:33:56 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/9/2021 1:02:25 PM
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 2/5/2021 5:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2021 6:03:35 AM
DewDiligence Member Level  Thursday, 11/05/20 05:58:09 PM
Re: None
Post # of 34 
ASMB—(-37%/AH)—suffers_massive_phase-2_failure in HBV:

https://www.globenewswire.com/news-release/2020/11/05/2121468/0/en/Assembly-Biosciences-Provides-Update-on-the-Ongoing-Phase-2-Extension-Study-of-Vebicorvir-in-Patients-with-Chronic-Hepatitis-B-Virus-Infection.html
Quote:
Assembly Biosciences…provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. A first of its kind, Study 211 is exploring whether sustained virologic response (SVR) could be achieved after discontinuing therapy in virologically-suppressed patients who had received at least 12-18 months of combination treatment with core inhibitor VBR and a nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI). Study patients who met the treatment stopping criteria discontinued therapy and have been assessed monthly for safety and relapse. The study has not achieved meaningful SVR rates as 39 of 41 patients have now relapsed.

I previously posted that ABI-H0731 appeared to have only modest efficacy (#msg-156515976), which is why ASMB has a backup CpAM compound for HBV called ABI-H2158. Today’s failure presumably spells the end of ABI-H0731 as a serious candidate.

Note: ENTA has an HBV CpAM in phase-2 that the CEO says is much more potent than ABI-H0731 (#msg-156787041).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences